WO2018182562A1 - Method of treatment of skin conditions of eye lids - Google Patents
Method of treatment of skin conditions of eye lids Download PDFInfo
- Publication number
- WO2018182562A1 WO2018182562A1 PCT/US2017/024201 US2017024201W WO2018182562A1 WO 2018182562 A1 WO2018182562 A1 WO 2018182562A1 US 2017024201 W US2017024201 W US 2017024201W WO 2018182562 A1 WO2018182562 A1 WO 2018182562A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- patient
- treatment
- eye lids
- tenting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/882—Mixing prior to application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Definitions
- This invention relates to a method of the treatment eye lids with nonsurgical blepharoplasty by injection to reverse skin tenting and upper eyelid overhang and lower lid laxity.
- the present invention is directed to a method for the non-surgical reduction of localized loose skin in the upper and lower lids that is associated with the normal aging loss of the integrity of the dermis that supports the epidermis.
- the upper lid tenting and overhang and lower lid tenting, overhang and laxity can give the appearance of one looking tired when not.
- a treatment for skin tenting, lid laxity, sag and overhang in the upper and lower lids of the eyes with an aqueous solution of citric acid with a viscosity consistent with water at 20 to 25°C.
- the Invention provides a method for improvement of the tired look of human skin of the eye lids comprising administering citric acid or a salt thereof to a patient in need thereof, wherein the administering is a subcutaneous injection.
- the method tightens subcutaneous fat via strengthening of wall proteins located in the hypodermis of the skin of the upper and lower eye lids to thereby enhance facial appearance.
- the injection is, for example, in the form of one or more large blebs or small boluses.
- the method may also include an additional step of measuring one or more improvements in the appearance of the skin with a measuring device.
- the citric acid or salt thereof When the citric acid or salt thereof is placed in the superficial plane or deep plains of subdermal fat, it causes skin tightening by connective tissue contractions, increase support of the subcutaneous tissue, and tensile strength to protein strands below the dermis.
- the citric acid or salt thereof may be either natural or synthetic.
- the compositions, treatment schedules and methods of using said compositions discovered by the inventor effectively remove the effect of tenting or impending tenting of the upper and lower lids.
- tenting and impending tenting and tented skin ptosis of the upper and lower lids of the eyes are a well-known beauty problems; problems that can progress to visual impairment if treatment to reverse the presentation of the tented and hanging skin is delayed.
- the effect of tightening tented and hanging skin with subcutaneous injections repositions fat and re- compartmentalizes fatty tissue in its more anatomically correct position.
- Citrate constituted with isotonic water and dextrose can stimulate elastin tensile strength below the dermis and above and below the muscle to tighten skin, decrease the appearance of aging, and contour deficiencies, fine lines and wrinkles. Citrate is found in the serum of individuals, but also can be manufactured and processed.
- composition of the instant application is based on 100 volume percent calculations.
- the composition of the instant application is comprised of: 10 volume percent: 3.2 % sodium citrate buffer.
- approximately .109 ml of sodium citrate buffer is used.
- Citric acid having the formula,
- the 3.2% sodium citrate buffer or citric acid is combined together with
- the invention also encompasses a kit.
- the kit includes the following items: 1). sodium citrate powder, or a solution thereof, pre-loaded into a 20 cc intravenous vial for dispensing, 2). an 8 to 10 cc syringe of a liquid volume comprising isotonic water, sodium chloride, glycerol and trace electrolytes; and an injector device to reconstitute the dry elements.
- the injector mixes the ingredients back and forth between two 10 cc syringes until the formula is reconstituted to a dose of 10ml prior to administration.
- the mixture should have a neutral pH prior to injection.
- the prepared solution should exhibit the viscosity of water at 20 to 25°C at the time of injection.
- composition of the instant application for the subcutaneous reversal of skin tenting, sag, lag of the upper and/or lower lid should be administered only by competent plastic surgeons, dermatologists or other medical doctors and their eligible licensed staff. Injections into the sub-dermal fat tissue in patients having skin tenting, sag or lag of the eye lids will tighten and thicken the subdermal fat bands and the hypodermis thereby reducing the appearance of fine lines, wrinkles, and pores of the eye lids.
- Formulations suitable for administration conveniently comprise sterile aqueous solutions of the active ingredient(s). Preparations may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
- Preparations can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
- the formulation may be presented in unit or multi-dose containers, for example, sealed ampoules or vials.
- An initial treatment period involves up to 2 to 3 treatments involving an initial treatment with usually two subsequent follow-up treatments, i.e. a follow-up treatment and a follow-up to the follow-up treatment.
- a follow-up treatment When the appearance of the correction of the subcutaneous wall protein deficit of the upper and lower lids is observed, treatment is usually halted.
- the consultant discusses the intended goals with the patient and then determines if the patient is a candidate for the follow-up to the follow-up treatment. The provider determines the appropriate number of milliliters of citric acid solution to be injected into the defective spaces of the subdermal fat planes; on average a range of 2 mis to 12 mis of citric acid solution is employed.
- a hypodermic need is used to inject the citric acid with sterile water as an aqueous mixture in a micro droplet and microfluidic pattern into the defective space in the orbital lids targeting the preaponeurotic fat pads, medial fat pads, temporal fat pads, medial fat pads as well as the fatty cell layers.
- the solution immediately reabsorbs into subdermal planes. Residual swelling will be appreciated for 24 hours followed by reabsorption of the solution.
- the initial, local inflammatory response heals at a varying rate depending on the individual patient with the majority of patients healing completely within two weeks or less. Results from the treatment can be appreciated in 4 to 6 weeks with maximum results in 12 months and beyond. Blood test can be used to monitor the dermal response to the treatment. Before and after photography is used to consult with the recipient in one month, three months, 12 months as recommended visits and a 24-month visit with photography is optional.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Percussion Or Vibration Massage (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for the hypodermis tightening of fat septa and the reduction of skin tenting, skin lag and skin overhang of the upper and lower eye lids.
Description
METHOD OF TREATMENT OF SKIN CONDITIONS OF EYE LIDS
STATEMENT AS TO THE RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
(0001] This invention was not made with U.S. government support.
FIELD OF THE INVENTION
[0002] This invention relates to a method of the treatment eye lids with nonsurgical blepharoplasty by injection to reverse skin tenting and upper eyelid overhang and lower lid laxity.
BACKGROUND
[0003J Overhang and tenting of the skin in the upper and lower lids of the eyes are unique phenomena that can occur in individuals that are not of an advanced age. The skin in the upper and lower lids of the eyes can be resistant to eye creams for the reduction of the presentation of skin tenting, overhang and laxity. There are no approved or rigorously evaluated non-surgical alternatives for treatment of these conditions directly at the source, i.e. the upper and lower lids. Surgical alternatives include various forms of upper and lower lid blepharoplasties where incisions are made and fat is surgically teased out of candidates. All surgeries, however, are associated with the known risks of anesthesia, infection, bleeding, bruising, scarring, as well as the possibility of poor outcome and the expected discomfort and "down-time" for the patient. Presently, there are no injections for the upper and lower lids that reverse skin tenting, laxity, overhang, sag or puffiness. There has been hesitation in the market to date for injections into the tissue proximal to the orbits of the eyes. Injections into this anatomical sight increase the risk of causing blindness in the patient. None of the cosmetic substances currently in the cosmetic injection market can be injected into the eye lids or the tissue proximal to the orbits of the eyes. There is a need in the market, therefore, for a non-surgical alternative to address skin conditions of the eye lids which does not pose the risk of causing blindness. A citrate solution however, could be used to successfully treat skin conditions of the eye lids without the risk of causing blindness in patients. The demand for nonsurgical eye correction is very high in the cosmetic market.
[00041 In spite of procedural risks, the growing appeal of cosmetic medical treatment of said procedures is a testament to the psychological importance of body image and the beneficial outcomes of these procedures, as perceived by the patients who seek them. However, the significance of a product that corrects signs of peri-orbital aging with little to no risk is significant.
BRIEF DESCRIPTION OF THE INVENTION
[00051 The present invention is directed to a method for the non-surgical reduction of localized loose skin in the upper and lower lids that is associated with the normal aging loss of the integrity of the dermis that supports the epidermis. The upper lid tenting and overhang and lower lid tenting, overhang and laxity can give the appearance of one looking tired when not. In particular, a treatment for skin tenting, lid laxity, sag and overhang in the upper and lower lids of the eyes with an aqueous solution of citric acid with a viscosity consistent with water at 20 to 25°C.
DETAILED DESCRIPTION OF THE INVENTION
[0006] The Invention provides a method for improvement of the tired look of human skin of the eye lids comprising administering citric acid or a salt thereof to a patient in need thereof, wherein the administering is a subcutaneous injection. The method tightens subcutaneous fat via strengthening of wall proteins located in the hypodermis of the skin of the upper and lower eye lids to thereby enhance facial appearance. The injection is, for example, in the form of one or more large blebs or small boluses. The method may also include an additional step of measuring one or more improvements in the appearance of the skin with a measuring device. When the citric acid or salt thereof is placed in the superficial plane or deep plains of subdermal fat, it causes skin tightening by connective tissue contractions, increase support of the subcutaneous tissue, and tensile strength to protein strands below the dermis. The citric acid or salt thereof may be either natural or synthetic.
[0007] The compositions, treatment schedules and methods of using said compositions discovered by the inventor effectively remove the effect of tenting or impending tenting of the upper and lower lids. Generally speaking, tenting and impending tenting and tented skin ptosis of the upper and lower lids of the eyes are a well-known beauty problems; problems that can progress to visual impairment if treatment to reverse the presentation of the tented and hanging skin is delayed. In addition, the effect of tightening tented and hanging skin with subcutaneous injections repositions fat and re- compartmentalizes fatty tissue in its more anatomically correct position.
[0008] Citrate constituted with isotonic water and dextrose can stimulate elastin tensile strength below the dermis and above and below the muscle to tighten skin, decrease the appearance of aging, and contour deficiencies, fine lines and wrinkles. Citrate is found in the serum of individuals, but also can be manufactured and processed.
[0009] The composition of the instant application is based on 100 volume percent calculations. In particular, the composition of the instant application is comprised of: 10 volume percent: 3.2 % sodium citrate buffer. In the preferred embodiment, approximately .109 ml of sodium citrate buffer is used. Citric acid, having the formula,
, may also be used.
The 3.2% sodium citrate buffer or citric acid is combined together with
90 volume percent: 36.6 % isotonic water, 45% sodium chloride and 6.4% glycerol with trace electrolytes.
[0010] The invention also encompasses a kit. The kit includes the following items: 1). sodium citrate powder, or a solution thereof, pre-loaded into a 20 cc intravenous vial for dispensing, 2). an 8 to 10 cc syringe of a liquid volume comprising isotonic water,
sodium chloride, glycerol and trace electrolytes; and an injector device to reconstitute the dry elements. The injector mixes the ingredients back and forth between two 10 cc syringes until the formula is reconstituted to a dose of 10ml prior to administration.
(0011] The mixture should have a neutral pH prior to injection. In addition, the prepared solution should exhibit the viscosity of water at 20 to 25°C at the time of injection.
[0012] The composition of the instant application for the subcutaneous reversal of skin tenting, sag, lag of the upper and/or lower lid should be administered only by competent plastic surgeons, dermatologists or other medical doctors and their eligible licensed staff. Injections into the sub-dermal fat tissue in patients having skin tenting, sag or lag of the eye lids will tighten and thicken the subdermal fat bands and the hypodermis thereby reducing the appearance of fine lines, wrinkles, and pores of the eye lids.
|0013] Formulations suitable for administration, conveniently comprise sterile aqueous solutions of the active ingredient(s). Preparations may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
Preparations can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use. The formulation may be presented in unit or multi-dose containers, for example, sealed ampoules or vials.
EXAMPLES
(0014) Prior to treatment, photographs are taken of the patient's eyelids. An initial treatment period involves up to 2 to 3 treatments involving an initial treatment with usually two subsequent follow-up treatments, i.e. a follow-up treatment and a follow-up to the follow-up treatment. When the appearance of the correction of the subcutaneous wall protein deficit of the upper and lower lids is observed, treatment is usually halted. At the initial treatment session, the consultant discusses the intended goals with the patient and then determines if the patient is a candidate for the follow-up to the follow-up treatment. The provider determines the appropriate number of milliliters of citric acid
solution to be injected into the defective spaces of the subdermal fat planes; on average a range of 2 mis to 12 mis of citric acid solution is employed. During treatment, a hypodermic need is used to inject the citric acid with sterile water as an aqueous mixture in a micro droplet and microfluidic pattern into the defective space in the orbital lids targeting the preaponeurotic fat pads, medial fat pads, temporal fat pads, medial fat pads as well as the fatty cell layers. The solution immediately reabsorbs into subdermal planes. Residual swelling will be appreciated for 24 hours followed by reabsorption of the solution. The initial, local inflammatory response heals at a varying rate depending on the individual patient with the majority of patients healing completely within two weeks or less. Results from the treatment can be appreciated in 4 to 6 weeks with maximum results in 12 months and beyond. Blood test can be used to monitor the dermal response to the treatment. Before and after photography is used to consult with the recipient in one month, three months, 12 months as recommended visits and a 24-month visit with photography is optional.
(0015] Example 1:
Claims
1. A method for improvement of the tired look of human skin comprising administering citric acid or a salt thereof to a patient in need thereof, wherein said administering is subcutaneous injection.
2. The method of claim I , wherein said administering tightens subcutaneous fat via strengthening of wall proteins located in the hypodermis of the upper and lower eye lids to thereby enhance facial appearance.
3. The method of claim 1 , wherein said injection is in the form of one or more blebs or boluses.
4. The method of claim 1 , further comprising measuring one or more improvements in the appearance of the skin with a measuring device.
5. The method of claim 1 , wherein said citric acid or salt thereof is places in the superficial plane or deep plains of subdermal fat thereby causing skin tightening by connective tissue contractions, increased support of subcutaneous tissue, and providing tensile strength to protein strands below the dermis.
6. The method of claim 1 , wherein citric acid or salt thereof is obtained from natural sources is synthetic.
7. The method according to claim 3, wherein said injection is administered to the eye lids of the patient in need of treatment.
8. The method according to claim 3, wherein said injection is administered to proximal to the orbit of the eyes of the patient in need of treatment.
9. The method according to claim 7, wherein said patient suffers from a condition of the eye lids selected from the group consisting of skin tenting, impending skin tenting, lid laxity, skin sag, ptosis or skin overhang.
10. The method according to claim 1 , wherein said method is administered to a patient in need thereof either before or after the patient undergoes blepharoplasty surgery of the eye lids.
1 1. The method according to claim 1 , wherein said method results in the repositioning of fat and/or re-compartmentalizing of fatty tissue in the eye lids of the patient undergoing said method.
12. A composition for treatment of conditions of the eye lids of human patients in need of treatment thereof, comprising 10% of 3.2% sodium citrate buffer, 36.6% isotonic water, 45% sodium chloride, 6.4% glycerol and trace electrolytes wherein said solution has a neutral pH.
13. The composition according to claim 12, wherein said composition has a viscosity similar to the viscosity of water at 20 to 25"C.
14. The composition according to claim 12, wherein said composition is used to treat certain conditions of the eye lids selected from the group consisting of skin tenting, impending skin tenting, lid laxity, skin sag, ptosis or skin overhang.
15. A kit comprising
a. a pre-filled intravenous vial containing a pre-determined amount of either sodium citrate powder or a solution of sodium citrate;
b. an intravenous vial containing a prepared solution of isotonic water, sodium chloride, glycerol and select electrolytes;
c. an injector to reconstitute the sodium citrate powder or solution with the prepared isotonic water/sodium chloride/glycerol/electrolyte solution; and
d. one or more syringes to administer the reconstituted components.
16. The method according to claim 3, wherein said injection is given to the patient in a 10 ml dose.
17. The method of claim 2, wherein said method is used for cosmetic purposes.
18. The method of claim 17, wherein said method results in the reduction of the appearance of fine lines, wrinkles and pores of the patient being treated with the method.
19. The method of claim 2, wherein said method is used as a preventive measure in a patient in need of such treatment wherein said patient suffers from a skin condition of the eye lids selected from the group consisting of skin tenting, impending skin tenting, lid laxity, skin sag, ptosis or skin overhang which can result in the impairment of the vision of the patient if said condition or condition are left untreated.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780090412.0A CN110582264B (en) | 2017-03-26 | 2017-03-26 | Method for treating eyelid skin condition |
EP17902778.4A EP3600233A4 (en) | 2017-03-26 | 2017-03-26 | Method of treatment of skin conditions of eye lids |
MX2019011603A MX2019011603A (en) | 2017-03-26 | 2017-03-26 | Method of treatment of skin conditions of eye lids. |
CA3056919A CA3056919A1 (en) | 2017-03-26 | 2017-03-26 | Method of treatment of skin conditions of eye lids |
PCT/US2017/024201 WO2018182562A1 (en) | 2017-03-26 | 2017-03-26 | Method of treatment of skin conditions of eye lids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/024201 WO2018182562A1 (en) | 2017-03-26 | 2017-03-26 | Method of treatment of skin conditions of eye lids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018182562A1 true WO2018182562A1 (en) | 2018-10-04 |
Family
ID=63678310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/024201 WO2018182562A1 (en) | 2017-03-26 | 2017-03-26 | Method of treatment of skin conditions of eye lids |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3600233A4 (en) |
CN (1) | CN110582264B (en) |
CA (1) | CA3056919A1 (en) |
MX (1) | MX2019011603A (en) |
WO (1) | WO2018182562A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019136393A1 (en) * | 2018-01-05 | 2019-07-11 | Stafford Vivi Robyn | Method of subcutaneous aqueous citric acid injection non-surgical skin tightening excluding orbit |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB815517A (en) * | 1955-06-20 | 1959-06-24 | Upjohn Co | Dihydro novobiocin, its salts and other derivatives and pharmaceutical compositions containing same |
CA2153553A1 (en) * | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Stable lipid emulsion |
CA2567803A1 (en) * | 2004-05-28 | 2005-12-15 | Schering Corporation | Injectable pharmaceutical suspension comprising posaconazole |
US20120121585A1 (en) * | 2010-11-15 | 2012-05-17 | Novartis Ag | SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES |
RU2512801C1 (en) * | 2012-10-08 | 2014-04-10 | Ирина Юрьевна Юхман | Therapeutic eye balsam |
US20140127227A1 (en) * | 2011-10-28 | 2014-05-08 | Byeong Seon Chang | Protein formulations containing amino acids |
US8846066B2 (en) * | 2004-05-19 | 2014-09-30 | The Regents Of The University Of California | Methods and related compositions for reduction of fat and skin tightening |
US20170087072A1 (en) * | 2015-09-29 | 2017-03-30 | Vivi Robyn Stafford | Sodium Citrate (Citric Acid) Injections, intramuscular, below the dermis and in the facial soft tissue to stimulate the new synthesis of collagen in the skin and hence causing skin tightening |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68906153T2 (en) * | 1988-02-26 | 1993-10-28 | Genentech Inc | HUMANES RELAXATION DEVICE. |
CA2552442A1 (en) * | 2002-12-31 | 2004-06-30 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
JP2004292400A (en) * | 2003-03-28 | 2004-10-21 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor and cosmetic composition or food |
ATE542537T1 (en) * | 2004-02-20 | 2012-02-15 | Human Matrix Sciences Llc | MANGANEOUS AND IRON BASED COMPOUNDS FOR ELASTOGENESIS AND TREATMENT OF CONNECTIVE TISSUE |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
US20070298005A1 (en) * | 2006-06-22 | 2007-12-27 | Marie-Josee Thibault | Injectable composition for treatment of skin defects or deformations |
US20130052244A1 (en) * | 2011-08-30 | 2013-02-28 | Mark Weinreb | Stem Cell Compositions and Methods |
WO2014201618A1 (en) * | 2013-06-18 | 2014-12-24 | 山东省生物药物研究院 | Use of xanthan gum in preparation of injectable beauty products |
AR102869A1 (en) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | QUICK ACTION INSULIN COMPOSITIONS |
TWI773641B (en) * | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | Aqueous suspension containing nano particles of glucocorticoids |
US20180078621A1 (en) * | 2016-09-22 | 2018-03-22 | Kyoung Lack Lee | Composition for hypotonic lipolysis and manufacturing method thereof |
-
2017
- 2017-03-26 MX MX2019011603A patent/MX2019011603A/en unknown
- 2017-03-26 EP EP17902778.4A patent/EP3600233A4/en not_active Withdrawn
- 2017-03-26 WO PCT/US2017/024201 patent/WO2018182562A1/en unknown
- 2017-03-26 CN CN201780090412.0A patent/CN110582264B/en active Active
- 2017-03-26 CA CA3056919A patent/CA3056919A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB815517A (en) * | 1955-06-20 | 1959-06-24 | Upjohn Co | Dihydro novobiocin, its salts and other derivatives and pharmaceutical compositions containing same |
CA2153553A1 (en) * | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Stable lipid emulsion |
US8846066B2 (en) * | 2004-05-19 | 2014-09-30 | The Regents Of The University Of California | Methods and related compositions for reduction of fat and skin tightening |
CA2567803A1 (en) * | 2004-05-28 | 2005-12-15 | Schering Corporation | Injectable pharmaceutical suspension comprising posaconazole |
US20120121585A1 (en) * | 2010-11-15 | 2012-05-17 | Novartis Ag | SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES |
US20140127227A1 (en) * | 2011-10-28 | 2014-05-08 | Byeong Seon Chang | Protein formulations containing amino acids |
RU2512801C1 (en) * | 2012-10-08 | 2014-04-10 | Ирина Юрьевна Юхман | Therapeutic eye balsam |
US20170087072A1 (en) * | 2015-09-29 | 2017-03-30 | Vivi Robyn Stafford | Sodium Citrate (Citric Acid) Injections, intramuscular, below the dermis and in the facial soft tissue to stimulate the new synthesis of collagen in the skin and hence causing skin tightening |
Non-Patent Citations (3)
Title |
---|
BERNSTEIN, EF ET AL.: "Citric Acid Increases Viable Epidermal Thickness and Glycosaminoglycan Content of Sundamaged Skin", DERMATOLOGIC SURGERY, vol. 23, August 1997 (1997-08-01), pages 689 - 694, XP055641872 * |
LAURSEN, T ET AL.: "Pain Perception after Subcutaneous Injections of Media Containing Different Buffers", BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY, 2006, XP055118277 * |
See also references of EP3600233A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019136393A1 (en) * | 2018-01-05 | 2019-07-11 | Stafford Vivi Robyn | Method of subcutaneous aqueous citric acid injection non-surgical skin tightening excluding orbit |
Also Published As
Publication number | Publication date |
---|---|
EP3600233A1 (en) | 2020-02-05 |
EP3600233A4 (en) | 2020-10-21 |
CN110582264A (en) | 2019-12-17 |
MX2019011603A (en) | 2021-08-16 |
CN110582264B (en) | 2022-11-11 |
CA3056919A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cohen | Understanding, avoiding, and managing dermal filler complications | |
Hwang | Periorbital injectables: understanding and avoiding complications | |
RU2690845C2 (en) | Method for stimulating hair growth and preventing hair loss of patient, substance therefor and method for producing substance | |
Tran et al. | Vision loss and blindness following fillers | |
Obagi et al. | Autologous fat augmentation of the face | |
Bravo et al. | Dermal thickness increase and aesthetic improvement with hybrid product combining hyaluronic acid and calcium hydroxyapatite: a clinical and sonographic analysis | |
RU2530629C2 (en) | Drug-induced lipoatrophy for cosmetic purposes | |
US9744110B2 (en) | Method of treating conditions of the eyelid | |
de Menezes Penedo et al. | Improvement of facial skin laxity by a combined technique with hyaluronic acid and calcium hydroxylapatite fillers: a clinical and ultrasonography analysis | |
EP3600233A1 (en) | Method of treatment of skin conditions of eye lids | |
Haq et al. | Multinational, multipatient study of calcium hydroxylapatite for treatment of the aging hand: European cosmetic physician group on hand augmentation | |
JP2021506985A (en) | Neurotoxin for use in minimizing scarring | |
Matthews-Brzozowska et al. | Mesotherapy–a method of facial skin rejuvenation from an interdisciplinary perspective on improving facial aesthetics | |
RU2238076C1 (en) | Method for treating and preventing diseases due to affecting biologically active points and areas | |
Hotta | Lip enhancement: physical assessment, injection techniques, and potential adverse events | |
Salahia et al. | Hyaluronic acid: a safe, biodegradable and biocompatible product for buttock augmentation and contouring | |
WO2015111034A1 (en) | Apparatus and methods for skin treatment, drug application and cream formulation | |
RU2826963C1 (en) | Method of carboxytherapy in treating patients with temporomandibular joint pain syndrome | |
RU2659959C1 (en) | Composition of the preparation for correction of skin defects | |
RU2723140C1 (en) | Method of non-surgical correction of face shape | |
US20200016056A1 (en) | Method of subcutaneous aqueous citric acid injection non-surgical skin tightening excluding orbit | |
Yanes et al. | Poly-L-Lactic Acid | |
Mariwalla et al. | Forehead Reflation | |
Abdelaziz et al. | A Comparative Study Between Effect of Follicular Unit Extraction Alone and Combined with Platelet Riched Plasma in Treatment of Androgeneitc Alopecia (A Trichoscopic Evaluation) | |
Baker | The use of hyaluronidase in aesthetic medicine: a literature review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17902778 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3056919 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017902778 Country of ref document: EP Effective date: 20191028 |